Supplementary Figures 1 - 5, Tables 1 - 3 from Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
Laurent Poirot(Txcell (France)), Julianne Smith(Case Western Reserve University), Román Galetto(Txcell (France)), Martin Pulé(Autolus (United Kingdom)), Cécile Bas(Txcell (France)), Justin Eyquem(Gladstone Institutes), Isabelle Chion-Sotinel(Txcell (France)), Sophie Derniame(Txcell (France)), Agnès Gouble(Txcell (France)), Aymeric Duclert(Txcell (France)), Andrew M. Scharenberg(CTI BioPharma (Italy)), Laëtitia Lemaire(Txcell (France)), Cécile Schiffer-Mannioui(Txcell (France)), Diane Le Clerre(Txcell (France)), Sylvain Arnould(Servier (France)), Pierrick Potrel(Txcell (France)), Céline Lebuhotel(Txcell (France)), Gordon Weng-Kit Cheung(CRUK Lung Cancer Centre of Excellence), Karl S. Peggs(Royal London Hospital), Brian Philip(CRUK Lung Cancer Centre of Excellence)
Cited by 0
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k